Sick and tired of dealing with generic drug shortages and unpredictable price increases, five large U.S. health systems are taking an unusual step: they’re forming their own nonprofit generic drugmaker.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The European Patent Office (EPO) has revoked a patent granted to the Broad Institute for fundamental aspects of the technology, in the latest installment of the CRISPR patent battle.
For those of you who haven’t experienced the process to secure Food and Drug Administration approval, it can be quite the minefield. Helping to solve those woes is new company Enzyme.com.
With the possibility that CRISPR-Cas9 could prove ineffective in humans, there was talk that the stocks of these biotechs could turn out to be worthless. But the cart got before the horse — by a few miles.
23andMe’s ancestry tests and those from three other companies produce drastically different results, according to Kristen Brown, writing for Gizmodo.
The good thing about J.P. Morgan Week is that it draws innovative people who want to invest. The question is, should healthcare capital be focused on solving big problems and getting rewarded for them, or just focused on the status quo?
Dawn Barry will be responsible for leading operations, communicating and implementing company mission, and guiding overall strategy, direction, and growth.
EncrpGen have come forward with a solution that allows you to take control of your own genetic makeup, after 23andMe faces backlash.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to reshuffle and renew her leadership team to shape the new strategic direction for the company’s pharmaceutical division. Following her inauguration, Walmsley has replaced about 50 of GSK’s top managers.
Artificial Intelligence (AI), Digitisation, Blockchain…which of these financial technology trends will experience the biggest growth of 2018.
Roche Diagnostics and GE Healthcare have announced a collaboration aimed at developing a digital diagnostics platform providing clinical decision platform to support precision medicine.
Invitae announces 2017 guidance, including delivering 110,000-120,000 billable reports and generating revenue between $55 million and $65 million.